Unicycive Therapeutics, Inc. (UNCY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor - The resubmission package includes 12 month

Event · Clinical / regulatory
Product
oxylanthanum carbonate
Milestone
NDA submission
Indication
hyperphosphatemia in patients with chronic kidney disease

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 29, 2026, 11:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 11:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UNCY
Neutral
high confidence
Mentioned
$UNCY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$UNCYNeutralMed
01

Why it matters

Regulatory progress is a primary catalyst for UNCY; investors will watch the FDA's response closely.

02

Market read

The filing provides fresh regulatory information that could move UNCY's price in the short term.

03

What to watch

Cash runway is sufficient only to H2 2027; financing needs could become a concern if approval is delayed.

Relevance 6/10Novelty 8/10Timing: today

Background

The 8‑K filing details the NDA resubmission, new CMC data, and the company's cash position.

Company-level read

Ticker impact

$UNCYNeutralHigh confidence
Context

Unicycive Therapeutics resubmitted its NDA for oxylanthanum carbonate with new manufacturing data and expects FDA acceptance within 30 days.

Expected impact

likely upward pressure if the FDA accepts the resubmission; downside risk if the agency raises further concerns.

Evidence & confidence

The filing provides fresh regulatory progress for a clinical-stage biotech, a key catalyst for valuation.

Market effects

Positive signal for the kidney‑disease therapeutic niche and may boost peer biotech sentiment.

U.S. biotech sector could see modest gains as investors price in potential approval.

Limited to biotech investors; no broad market impact.

Counterpoint

If the original vendor fails inspection, the FDA may delay approval, negating the benefit of the new vendor.

Key entities

  • Unicycive Therapeutics, Inc.

    Clinical‑stage biotech developing oxylanthanum carbonate for hyperphosphatemia.

Related articles

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.

$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.

$UNCYMedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA acceptance of its resubmitted NDA for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a PDUFA date of March 25, 2027. The resubmission includes new manufacturing data. The company hopes for potential approval, pending FDA review and possible inspections.

$UNCYHighAI 8/10

Why is Unicycive Therapeutics stock rallying today?

Unicycive Therapeutics (UNCY) stock rose 3.5% after the FDA accepted its resubmission for oxylanthanum carbonate, a treatment for chronic kidney disease. The FDA set a March 2027 target action date. The resubmission includes new manufacturing data addressing prior deficiencies. The broader market also gained, supporting small-cap biotech stocks. The company faces ongoing legal action, capping gains.